IBRX

SEC source: 0001326110-24-000014 · wk-form4_1706920419.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,838

SEC source: 0001326110-24-000014 · wk-form4_1706920419.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,673

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · derivative · entry 3

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.

SEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · nonDerivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,334

SEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,804

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-24-000008 · wk-form4_1704336100.xml · derivative · entry 3

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,396

Underlying: Common Stock · 30,397 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3 · derivative.exercise_date: 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

F3 · derivative.expiration_date: 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

SEC source: 0001326110-24-000008 · wk-form4_1704336100.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,928

F1 · price: On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-24-000008 · wk-form4_1704336100.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,697

Underlying: Common Stock · 34,483 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

SEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · nonDerivative · entry 2

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,969

F1 · price: On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · nonDerivative · entry 1

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-24-000009 · wk-form4_1704336782.xml · derivative · entry 2

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-12-31

F3 · kind: In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025. Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share.

F3 · reported_value: In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025. Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share.

F3 · derivative.expiration_date: In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025. Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share.

F3 · underlyingValue: In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025. Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share.

F4 · ownership.nature: Convertible Promissory Note, dated as of March 31, 2023, as amended, held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0001326110-24-000009 · wk-form4_1704336782.xml · derivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-12-31

F1 · kind: On December 29, 2023, in connection with the Issuer entering into a Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (the "RIPA"), the Issuer and Nant Capital, LLC ("Nant Capital") entered into an Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to extend the maturity dates of certain existing promissory notes held by Nant Capital from December 31, 2024 to December 31, 2025, and to allow Nant Capital, in its sole discretion, to convert up to an aggregate of $380 million of principal, plus accrued and unpaid interest thereon, into shares of Issuer's Common Stock at a price per share equal to $8.27.

F1 · underlyingValue: On December 29, 2023, in connection with the Issuer entering into a Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (the "RIPA"), the Issuer and Nant Capital, LLC ("Nant Capital") entered into an Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to extend the maturity dates of certain existing promissory notes held by Nant Capital from December 31, 2024 to December 31, 2025, and to allow Nant Capital, in its sole discretion, to convert up to an aggregate of $380 million of principal, plus accrued and unpaid interest thereon, into shares of Issuer's Common Stock at a price per share equal to $8.27.

F2 · ownership.nature: Amended and Restated Promissory Note, dated as of December 29, 2023, held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0001326110-23-000149 · wk-form4_1703022089.xml · derivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,031

Underlying: Common Stock · 21,030 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.

SEC source: 0001326110-23-000149 · wk-form4_1703022089.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 15

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2026-09-11

F15 · derivative.exercise_date: That date upon which an amendment to the Issuers Certificate of Incorporation, as amended, becomes effective pursuant to which the number of authorized shares of the Issuer's common stock is increased from 900,000,000 to 1,350,000,000.

F16 · derivative.underlying_shares: Reporting person has the right at any time after the Conversion Date and on or before September 11, 2026 to convert all (but not less than all) of the outstanding principal amount of this Convertible Promissory Note (the "Note") and all (but not less than all) accrued and unpaid interest on this Note into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $1.935.

F17 · ownership.nature: Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 14

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-09-30

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F10 · reported_value: Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023.

F1 · derivative.underlying_shares: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F14 · ownership.nature: Second Amended and Restated Convertible Promissory Note held by NCSC. NantBio is the sole stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 13

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-09-30

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F10 · reported_value: Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023.

F1 · derivative.underlying_shares: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F13 · ownership.nature: Second Amended and Restated Convertible Promissory Note held by NantMobile. NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 12

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-09-30

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F10 · reported_value: Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023.

F1 · derivative.underlying_shares: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F12 · ownership.nature: Second Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 11

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-09-30

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F10 · reported_value: Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023.

F1 · derivative.underlying_shares: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F11 · ownership.nature: Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0000950170-23-048020 · ownership.xml · derivative · entry 10

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-09-30

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F10 · reported_value: Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023.

F1 · derivative.underlying_shares: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F11 · ownership.nature: Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0000950170-23-048020 · ownership.xml · nonDerivative · entry 3

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 32,606,985

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F4 · ownership.nature: Shares held by NCSC. NantBio, Inc. ("NantBio") is the sole stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.

SEC source: 0000950170-23-048020 · ownership.xml · nonDerivative · entry 2

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 47,557,934

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F3 · ownership.nature: Shares held by NantMobile. NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.

SEC source: 0000950170-23-048020 · ownership.xml · nonDerivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 129,227,017

F1 · kind: On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC ("Nant Capital"), NantMobile, LLC ("NantMobile") and NantCancerStemCell, LLC ("NCSC" and together with Nant Capital and NantMobile, the "Purchasers"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the "Notes," at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes.

F2 · ownership.nature: Shares held by Nant Capital, an investment vehicle of the reporting person.

SEC source: 0001326110-23-000113 · wk-form4_1694043530.xml · derivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,200

Underlying: Common Stock · 57,199 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000113 · wk-form4_1694043530.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,088,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-23-000115 · wk-form4_1694043655.xml · derivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,745

Underlying: Common Stock · 70,744 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024.

SEC source: 0001326110-23-000115 · wk-form4_1694043655.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,042

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-23-000114 · wk-form4_1694043604.xml · derivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,872

Underlying: Common Stock · 32,872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000114 · wk-form4_1694043604.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,902

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-23-000108 · wk-form4_1693270861.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,399

Underlying: Common Stock · 114,399 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award shall vest on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award shall vest on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000107 · wk-form4_1693270788.xml · derivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,744

Underlying: Common Stock · 65,744 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award shall vest on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award shall vest on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000106 · wk-form4_1693270702.xml · derivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,489

Underlying: Common Stock · 141,489 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000092 · wk-form4_1686951925.xml · derivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,061

Underlying: Common Stock · 21,030 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.

SEC source: 0001326110-23-000092 · wk-form4_1686951925.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,030

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

SEC source: 0001326110-23-000090 · wk-form4_1686868200.xml · derivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000089 · wk-form4_1686868141.xml · derivative · entry 1

MAXWELL LINDA · CIK 0001822674 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000088 · wk-form4_1686868079.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000087 · wk-form4_1686868013.xml · derivative · entry 1

Clark Wesley · CIK 0001349193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000086 · wk-form4_1686867937.xml · derivative · entry 1

Brennan John Owen · CIK 0001849620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000084 · wk-form4_1686867846.xml · derivative · entry 1

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,263

Underlying: Common Stock · 158,263 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 3

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 71,915

SEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 2

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 71,430

SEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 1

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 23,430

SEC source: 0001326110-23-000071 · wk-form4_1686009350.xml · nonDerivative · entry 3

Brennan John Owen · CIK 0001849620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

SEC source: 0001326110-23-000071 · wk-form4_1686009350.xml · nonDerivative · entry 2

Brennan John Owen · CIK 0001849620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001326110-23-000071 · wk-form4_1686009350.xml · nonDerivative · entry 1

Brennan John Owen · CIK 0001849620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001326110-23-000070 · wk-form4_1686009278.xml · nonDerivative · entry 1

Clark Wesley · CIK 0001349193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

SEC source: 0001326110-23-000066 · wf-form4_168428341644684.xml · derivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2023-12-31

F1 · underlyingValue: On May 12, 2023, the conversion price of the convertible promissory note previously issued on March 31, 2023 was fixed at $2.28 per share and the lender has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. Dollar amount shown reflects the aggregate principal and interest accrued as of May 12, 2023.

F2 · ownership.nature: Convertible Promissory Note held by Nant Capital, LLC, an investment vehicle of the reporting person.

SEC source: 0001326110-23-000010 · wf-form4_167581216683429.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,334

Underlying: Common Stock · 83,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021.